Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 6Completed 3Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 3

Interventions

rozanolixizumab 5zilucoplan 4eculizumab 4Rituximab 4Immunoglobulins, Intravenous 4efgartigimod alfa 3Tacrolimus 3Mycophenolic Acid 3Hizentra 3HBM9161 3Data Collection 2Azathioprine 2tofacitinib 1telitacicept 1ravulizumab 1iscalimab 1gamma-Globulins 1apraclonidine 1Thymectomy 1Telemedicine 1Sugammadex 1Sodium Chloride 1Pyridostigmine Bromide 1Prednisone 1Prednisolone 1Plasmapheresis 1Plasma Exchange 1Neurofeedback 1Neostigmine 1Muscle Stretching Exercises 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Myasthenia Gravis × efgartigimod alfa × Clear all
NCT02965573 2024-08-28

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

argenx

Phase 2 Completed
24 enrolled 28 charts

Myasthenia Gravis

NCT03770403 2023-07-14

ADAPT+

argenx

Phase 3 Completed
151 enrolled 11 charts

Myasthenia Gravis

NCT03669588 2022-02-08

ADAPT

argenx

Phase 3 Completed
167 enrolled 18 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡